Please try another search
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington. On December 19, 2023, Impel Pharmaceuticals Inc, along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas. The plan was later approved as Chapter 11 liquidation on April 1, 2024.
Name | Age | Since | Title |
---|---|---|---|
Robert E. Mittendorff | 44 | 2018 | Director |
Aaron Royston | 36 | 2016 | Director |
Timothy S. Nelson | 60 | 2017 | Independent Director |
Stewart J. Tepper | - | - | Member of Scientific Advisory Board |
Robert A. Hauser | - | - | Member of Scientific Advisory Board |
Greg Davis | - | - | Member of Scientific Advisory Board |
Ali J. Satvat | 46 | 2018 | Independent Director |
Darren S. Cline | 59 | 2023 | Independent Director |
Craig A. Erickson | - | 2022 | Member of Scientific Advisory Board |
Leslie S. Zun | - | - | Member of Scientific Advisory Board |
Diane E. Wilfong | 61 | 2019 | Independent Director |
David Allison | 41 | 2019 | Lead Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review